1. Home
  2. NET vs VRTX Comparison

NET vs VRTX Comparison

Compare NET & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cloudflare Inc.

NET

Cloudflare Inc.

HOLD

Current Price

$360.60

Market Cap

124.3B

Sector

Technology

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$504.13

Market Cap

128.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NET
VRTX
Founded
2009
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
124.3B
128.8B
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
NET
VRTX
Price
$360.60
$504.13
Analyst Decision
Buy
Buy
Analyst Count
34
32
Target Price
$336.81
★ $571.39
AVG Volume (30 Days)
★ 2.6M
858.7K
Earning Date
10-29-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 836.54
EPS
N/A
★ 8.33
Revenue
$2,167,937,000.00
★ $2,488,652,000.00
Revenue This Year
$32.46
$10.39
Revenue Next Year
$28.71
$9.83
P/E Ratio
★ N/A
$60.90
Revenue Growth
29.85
★ 46.20
52 Week Low
$158.83
$400.86
52 Week High
$367.43
$560.25

Technical Indicators

Market Signals
Indicator
NET
VRTX
Relative Strength Index (RSI) 64.39 39.15
Support Level $163.46 $501.01
Resistance Level $367.43 $506.93
Average True Range (ATR) 16.35 11.39
MACD 0.78 -1.85
Stochastic Oscillator 87.34 22.70

Price Performance

Historical Comparison
NET
VRTX

About NET Cloudflare Inc.

Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, builds on this infrastructure by enabling clients to deploy and run code without the need to manage or maintain servers.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: